| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1029 | 2019 |
| Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer KC Arbour, L Mezquita, N Long, H Rizvi, E Auclin, A Ni, G Martínez-Bernal, ... Journal of Clinical Oncology 36 (28), 2872-2878, 2018 | 871 | 2018 |
| Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ... Journal of Clinical Oncology 39 (30), 3391, 2021 | 437 | 2021 |
| Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation PA Jänne, GJ Riely, SM Gadgeel, RS Heist, SHI Ou, JM Pacheco, ... New England Journal of Medicine 387 (2), 120-131, 2022 | 417 | 2022 |
| Unravelling the biology of SCLC: implications for therapy JK Sabari, BH Lok, JH Laird, JT Poirier, CM Rudin Nature reviews Clinical oncology 14 (9), 549-561, 2017 | 416 | 2017 |
| Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis G Rodrigues, A Hoshino, CM Kenific, IR Matei, L Steiner, D Freitas, ... Nature cell biology 21 (11), 1403-1412, 2019 | 310 | 2019 |
| PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers JK Sabari, GC Leonardi, CA Shu, R Umeton, J Montecalvo, A Ni, R Chen, ... Annals of Oncology 29 (10), 2085-2091, 2018 | 265 | 2018 |
| First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1) SHI Ou, PA Jänne, TA Leal, II Rybkin, JK Sabari, MA Barve, L Bazhenova, ... Journal of Clinical Oncology 40 (23), 2530, 2022 | 174 | 2022 |
| Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ... Cancer discovery 8 (6), 686-695, 2018 | 169 | 2018 |
| KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non–small-cell lung cancer (NSCLC) harboring KRAS G12C mutation PA Jänne, II Rybkin, AI Spira, GJ Riely, KP Papadopoulos, JK Sabari, ... European Journal of Cancer 138, S1-S2, 2020 | 134 | 2020 |
| Immunophenotype and response to immunotherapy of RET-rearranged lung cancers M Offin, R Guo, SL Wu, J Sabari, JD Land, A Ni, J Montecalvo, ... JCO precision oncology 3, 2019 | 122 | 2019 |
| A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers JK Sabari, M Offin, D Stephens, A Ni, A Lee, N Pavlakis, S Clarke, ... JNCI: Journal of the National Cancer Institute 111 (6), 575-583, 2019 | 121 | 2019 |
| Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ... Clinical Cancer Research 25 (4), 1248-1260, 2019 | 113 | 2019 |
| Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers A Drilon, I Bergagnini, L Delasos, J Sabari, KM Woo, A Plodkowski, ... Annals of Oncology 27 (7), 1286-1291, 2016 | 103 | 2016 |
| JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). EB Haura, BC Cho, JS Lee, JY Han, KH Lee, RE Sanborn, R Govindan, ... Journal of Clinical Oncology 37 (15_suppl), 9009-9009, 2019 | 98 | 2019 |
| Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer JK Sabari, V Velcheti, K Shimizu, MR Strickland, RS Heist, M Singh, ... Clinical Cancer Research 28 (15), 3318-3328, 2022 | 91 | 2022 |
| KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors … TS Bekaii-Saab, AI Spira, R Yaeger, GL Buchschacher, AJ McRee, ... J Clin Oncol 40 (4_suppl), 519-519, 2022 | 91 | 2022 |
| 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring … GJ Riely, SHI Ou, I Rybkin, A Spira, K Papadopoulos, JK Sabari, ... Journal of Thoracic Oncology 16 (4), S751-S752, 2021 | 81 | 2021 |
| Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study WV Lai, L Lebas, TA Barnes, J Milia, A Ni, O Gautschi, S Peters, R Ferrara, ... European Journal of Cancer 109, 28-35, 2019 | 80 | 2019 |
| Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential … J Bauml, BC Cho, K Park, KH Lee, EUNK Cho, DW Kim, SW Kim, ... Journal of Clinical Oncology 39 (15_suppl), 9006-9006, 2021 | 79 | 2021 |
